65,437 trials
Metastatic Castration-Resistant Prostate Cancer
Primary: Percentage of Participants With Confirmed Objective Response (Objective Response Rate [ORR]) — 6.8 percentage of participants
BK Virus Infection
Primary: Time (Weeks) to Decrease of BKV Plasma Viral Load by 1 Log — 19.61; 10.80; 18.25 Weeks — p=0.1866
Atopic Dermatitis
Primary: Percent Change From Baseline to Week 16 in Eczema Area and Severity Index (EASI) Score — -49.38; -41.63; -55.70; -47.40 percent change — p=0.4498
Spinal Cord Injury
Primary: Change in Areal Bone Mineral Density at Hip — 0.92; -12.0; 1.19; -12.9 percentage change
Vasomotor Symptoms · Hot Flashes · Menopause
Primary: Reduction in Hot Flash Severity Score Based on Diary Data — -0.39; -0.38 score on a scale
Sexually Transmitted Diseases
Primary: Rectal Doxycycline Concentration — 0.654 µg/g
Primary Myelofibrosis (PMF) · Post-polycythemia Vera (Post-PV) · Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)
Primary: Splenic Response Rate at Week 24 — 7; 3; 97; 49 Participants — p=0.90
Leptin Receptor Deficiency Obesity
Primary: Percentage of Participants Who Reached ≥10% Weight Loss Threshold After 1 Year (Pivotal Cohort) — 45.5 percentage of participants — p=0.0001
Solid Tumor
Primary: Maximum Observed Concentration (Cmax) of Pamiparib in Plasma for Part A — 1970; 1820 ng/mL
Paroxysmal Nocturnal Hemoglobinuria
Primary: LDH Level at Week 27 (Parallel Comparison) — 205.69; 193.53 U/L
Colon Cancer · Rectal Cancer · Colonic Diverticulosis
Primary: Patient Satisfaction Scores (Absolute Value) — 98.0; 83.9; 98.1; 79.2 score on a scale
Persistent Asthma
Primary: Change in Mean Total Nasal Symptom Score (TNSS) From Baseline to 12 Months Between Cockroach SCIT and Placebo — -1.02; -0.79 score on a scale — p=0.63
Idiopathic Parkinson Disease
Primary: Change From Baseline to Week 16 in Pain Severity (NRS-11 Scale) - Full Analysis Set — -1.6; -0.8 score on a scale — p=0.1695
Obesity · Weight Loss · Diet Modification
Primary: Change in Expanded Short Physical Performance Battery Score — 0.06; 0.11; 0.16 score on a scale — p=0.16
Cardiovascular Diseases · Hepatitis C · Hiv
Primary: Change in Cardiovascular Disease Risk From Baseline to After Functional Cure of Hepatitis C, as Measured by High-sensitivity C-reactive Protein — 0.6; 0 mg/L